New Delhi: Zydus Lifesciences has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease (CKD)-induced osteoporosis. As per the agreement, Zydus and CDRI will jointly undertake preclinical research on the drug.
According to Pankaj Patel, Chairman of Zydus Lifesciences, CKD affects over 10 percent of the global population. The disease causes a progressive loss of kidney function and can consequently lead to kidney failure.
Under the initiative, CSIR-CDRI biomedical research expertise will be combined with Zydus’s innovative approach to drug discovery and development. The entities will together explore avenues for treating bone metabolism disorders in order to ensure that CKD patients have access to effective and affordable treatment procedures that improve their quality of life.
